[go: up one dir, main page]

AR078887A1 - Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen. - Google Patents

Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.

Info

Publication number
AR078887A1
AR078887A1 ARP100104083A ARP100104083A AR078887A1 AR 078887 A1 AR078887 A1 AR 078887A1 AR P100104083 A ARP100104083 A AR P100104083A AR P100104083 A ARP100104083 A AR P100104083A AR 078887 A1 AR078887 A1 AR 078887A1
Authority
AR
Argentina
Prior art keywords
oxo
dihydro
group
alkyl
optionally
Prior art date
Application number
ARP100104083A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41683136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078887(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Vitae Pharmaceuticals Inc filed Critical Boehringer Ingelheim Int
Publication of AR078887A1 publication Critical patent/AR078887A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En particular, los compuestos son inhibidores de 11beta-hidroxiesteroide deshidrogenasa (HSD) 1 y por lo tanto son adecuados para el tratamiento y prevencion de enfermedades que pueden influenciarse por la inhibicion de esta enzima, tal como enfermedades metabolicas, en particular diabetes tipo 2, obesidad y dislipidemia. Reivindicacion 1: Los compuestos de formula (1) en la que R1 se selecciona entre el grupo R1a que consiste en fenilo, naftilo, pirrolilo, furanilo, tienilo, piridilo, indolilo, benzofuranilo, benzotiofenilo, quinolinilo, isoquinolinilo, en el que en el grupo pirrolilo, furanilo, tienilo y piridilo, opcionalmente 1 o 2 grupos CH pueden estar reemplazados con N y en el que en el grupo indolilo, benzofuranilo, benzotiofenilo, quinolinilo e isoquinolinilo, de 1 a 3 grupos CH pueden estar reemplazados opcionalmente con N, 2-oxo-1,2-dihidro-piridinilo, 4-oxo-1,4-dihidro-piridinilo, 3-oxo-2,3-dihidro-piridazinilo, 3,6-dioxo-1,2,3,6-tetrahidro-piridazinilo, 2-oxo-1,2-dihidro-pirimidinilo, 4-oxo-3,4-dihidro-pirimidinilo, 1,2,3,4-tetrahidro-2,4-dioxo-pirimidinilo, 2-oxo-1,2-dihidro-pirazinilo, 2,3-dioxo-1,2,3,4-tetrahidro-pirazinilo, indanilo, 1-oxo-indanilo, 2,3-dihidro-indolilo, 2,3-dihidro-isoindolilo, 2-oxo-2,3-dihidro-indolilo, 1-oxo-2,3-dihidro-isoindolilo, 2,3-dihidrobenzofuranilo, 2-oxo-2,3-dihidro-benzoimidazolilo, 2-oxo-2,3-dihidro-benzoxazolilo, benzo[1,3]dioxolilo, 2-oxo-benzo[1,3]dioxolilo, 1,2,3,4-tetrahidro-naftilo, 1,2,3,4-tetrahidro-quinolinilo, 2-oxo-1,2,3,4-tetrahidro-quinolinilo, 2-oxo-1,2-dihidro-quinolinilo, 4-oxo-1,4-dihidro-quinolinilo, 1,2,3,4-tetrahidro-isoquinolinilo, 1-oxo-1,2,3,4-tetrahidro-isoquinolinilo, 1-oxo-1,2-dihidro-isoquinolinilo, 4-oxo-1,4-dihidro-cinnolinilo, 2-oxo-1,2-dihidro-quinazolinilo, 4-oxo-1,4-dihidro-quinazolinilo, 2,4-dioxo-1,2,3,4-tetrahidro-quinazolinilo, 2-oxo-1,2-dihidro-quinoxalinilo, 3-oxo-1,2,3,4-tetrahidro-quinoxalinilo, 2,3-dioxo-1,2,3,4-tetrahidro-quinoxalinilo, 1-oxo-1,2-dihidro-ftalazinilo, 1,4-dioxo-1,2,3,4-tetrahidro-ftalazinilo, cromanilo, coumarinilo, 2,3-dihidro-benzo[1,4]dioxin-ilo, 3-oxo-3,4-dihidro-benzo[1,4]oxazinilo, tetrazolilo, 2-oxo-2,3-dihidro-benzotiazolilo, e imidazo[1,2-a]piridinilo, en el que los miembros del grupo R1a están acoplados al grupo carbonitrilo en formula (1) mediante un átomo de carbono aromático y en el que los miembros del grupo R1a pueden estar opcionalmente sustituido con un R5, de uno a 3 R6 iguales y/o diferentes, y/o un R7, con la condicion de que en el caso de que R1 sea un grupo fenilo, los sustituyentes R5, R6 y/o R7 no estén acoplados con los átomos de carbono adyacentes al átomo de carbono que está acoplado con el grupo carbonitrilo en la formula (1); R2 se selecciona entre el grupo R2a que consiste en hidrogeno, halogeno, (het)arilo, ciano, nitro, amino, hidroxi, alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, y alquinilo C2-6, en el que en cada grupo alquil C1-6, cicloalquil C3-6, alquenil C2-6 o alquinil C2-6, un grupo CH2 puede estar opcionalmente reemplazado por CO o SO2, un grupo CH2 opcionalmente por O o NRN y un grupo CH opcionalmente por N y en el que cada uno de estos grupos puede estar opcionalmente mono- o polifluorado y opcionalmente mono- o independientemente de los otros disustituido con cloro, alquilo C1-3, ciano, (het)arilo, amino, alquilamino C1-3, di-(alquil C1-3)-amino, hidroxi, alquiloxi C1-3, (het)ariloxi, alquilsulfanilo C1-3, alquilsulfinilo C1-3 o cicloalquilo C3-6, en los que uno o dos grupos CH2 del grupo cicloalquilo C3-6 puede estar opcionalmente reemplazado independientemente de los otros con carbonilo, O o NRN y un grupo CH opcionalmente con N, y que puede estar independientemente mono- o independientemente disustituido con fluor o alquilo C1-3; R3, R4 se seleccionan, independientemente entre sí, entre el grupo R3/4a que consiste en hidrogeno, halogeno, alquilo C1-3, trifluorometilo, hidroxi, alquiloxi C1-3 y ciano o R3/4a representa R3 y R4 que están enlazados a átomos de carbono adyacentes y se unen para formar un grupo metilenodioxi, etilenodioxi o alquileno C3-5, cada uno de los cuales puede estar opcionalmente sustituido con uno o dos grupos seleccionados independientemente entre fluor y metilo o, junto con los átomos de carbono a los que están acoplados, forman un anillo benzo, pirido, pirimido, pirazino, piridazino, pirazolo, imidazo, triazolo, oxazolo, tiazolo, isoxazolo o isotiazolo, cada uno de los cuales puede estar opcionalmente sustituido con uno o dos sustituyentes seleccionados independientemente entre halogeno, alquilo C1-3, trifluorometilo, amino, alquilamino C1-3, di-(alquil C1-3)amino, hidroxi y alquiloxi C1-3; R5 se selecciona entre el grupo R5a que consiste en halogeno, (het)arilo, ciano, nitro, amino, hidroxi, alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6 y alquinilo C2-6, en el que en cada grupo, un grupo CH2 puede estar opcionalmente reemplazado con CO o SO2, un grupo CH2 opcionalmente con O o NRN y un grupo CH opcionalmente con N, y en el que cada uno de esos grupos puede estar opcionalmente mono- o polifluorado y opcionalmente mono- o disustituido independientemente de los otros con cloro, alquilo C1-3, ciano, (het)arilo, amino, alquilamino C1-3, di-(alquil C1-3)-amino, hidroxi, alquiloxi C1-3, (het)ariloxi, alquilsulfanilo C1-3, alquilsulfinilo C1-3 o cicloalquilo C3-6, en el que uno o dos grupos CH2 del grupo cicloalquilo C3-6 puede estar opcionalmente reemplazado independientemente de los otros con carbonilo, O o NRN y un grupo CH opcionalmente con N, y que puede estar opcionalmente mono- o independientemente disustituido con fluor o alquilo C1-3; R6, R7 se seleccionan, independientemente entre sí, entre el grupo R6/7a que consiste en halogeno, alquilo C1-3, alquinilo C2-3, trifluorometilo, hidroxi, alquiloxi C1-3 y ciano y/o R6/7a representa un R6 combinado con R7, que están unido a átomos de carbono adyacentes, que forman un grupo metilenodioxi, difluorometilenodioxi, etilenodioxi, alquileno C3-5, o forman, junto con los átomos de carbono a los que están acoplados, un anillo pirazolo, imidazo, oxazolo, isoxazolo, tiazolo o isotiazolo, cada uno de los cuales puede estar opcionalmente mono- o disustituido independientemente de los otros con alquilo C1-3, trifluorometilo, amino, alquilamino C1-3, di-(alquil C1-3)amino, hidroxi, alquiloxi C1-3; RN se selecciona, independientemente entre sí, entre el grupo RNa que consiste en hidrogeno, alquilo C1-6, cicloalquilo C3-6, alquenilo C3-6, alquinilo C3-6, (het)arilo, alquilcarbonilo C1-4, (het)arilcarbonilo, alquilaminocarbonilo C1-4, di-(alquil C1-3)-aminocarbonilo, (het)arilaminocarbonilo, alquiloxicarbonilo C1-4, alquilsulfonilo C1-4 y (het)arilsulfonilo, en el que cada grupo alquilo, alquenilo y alquinilo puede estar opcionalmente mono- o polisustituido con fluor y opcionalmente monosustituido con (het)arilo, ciano, aminocarbonilo, alquilaminocarbonilo C1-3, di-(alquil C1-3)aminocarbonilo, carboxi, alquiloxicarbonilo C1-4, amino, alquilamino C1-4, di-(alquil C1-3)amino, alquilcarbonilamino C1-4, hidroxi, alquiloxi C1-4, alquilsulfanilo C1-4, alquilsulfinilo C1-4, o alquilsulfonilo C1-4; (het)arilo se selecciona, independientemente entre sí, entre el grupo HAa que consiste en fenilo, naftilo, pirrolilo, furanilo, tienilo, piridilo, indolilo, benzofuranilo, benzotiofenilo, quinolinilo, isoquinolinilo, en el que en el grupo pirrolilo, furanilo, tienilo y piridilo, opcionalmente 1 o 2 grupos CH pueden estar reemplazados con N, y en el que en el grupo indolilo, benzofuranilo, benzotiofenilo, quinolinilo e isoquinolinilo, de 1 a 3 grupos CH pueden estar reemplazados opcionalmente con N, 2-oxo-1,2-dihidro-piridinilo, 4-oxo-1,4-dihidro-piridinilo, 3-oxo-2,3-dihidro-piridazinilo, 3,6-dioxo-1,2,3,6-tetrahidro-piridazinilo, 2-oxo-1,2-dihidro- pirimidinilo, 4-oxo-3,4-dihidro-pirimidinilo, 2,4-dioxo-1,2,3,4-tetrahidro-pirimidinilo, 2-oxo-1,2-dihidro-pirazinilo, 2,3-dioxo-1,2,3,4-tetrahidro- pirazinilo, 2-oxo-2,3-dihidro-indolilo, 2,3-dihidrobenzo-furanilo, 2-oxo-2,3-dihidro-benzoimidazolilo, 2-oxo-2,3-dihidro-benzoxazolilo, 2-oxo-1,2- dihidro-quinolinilo, 4-oxo-1,4-dihidro-quinolinilo, 1-oxo-1,2-dihidro-isoquinolinilo, 4-oxo-1,4-dihidro-cinnolinilo, 2-oxo-1,2-dihidro-quinazolinilo, 4-oxo-1,4-dihidro-quinazolinilo, 2,4-dioxo-1,2,3,4-tetrahidro-quinazolinilo, 2-oxo-1,2-dihidro-quinoxalinilo, 3-oxo-1,2,3,4-tetrahidro-quinoxalinilo, 2,3-dioxo-1,2,3,4-tetrahidro-quinoxalinilo, 1-oxo-1,2-dihidro-ftalazinilo, 1,4-dioxo-1,2,3,4-tetrahidro-ftalazinilo, cromanilo, coumarinilo, 2,3-dihidro-benzo[1,4jdioxinilo, 3-oxo-3,4-dihidro-benzo[1,4]oxazinilo y tetrazolilo, y en el que los grupos (het)arilo mencionados anteriormente pueden estar opcionalmente sustituidos con uno a tres R10 que pueden ser iguales o diferentes; R10 se selecciona, independientemente entre sí, entre el grupo R10a que consiste en halogeno, alquilo C1-3, difluorometilo, trifluorometilo, ciano, aminocarbonilo, alquilaminocarbonilo C1-3, di-(alquil C1-3)-aminocarbonilo carboxi, alquiloxicarbonilo C1-4, nitro, amino, alquilamino C1-3, di-(alquil C1-3)amino, acetilamino, metilsulfonilamino, hidroxi, alquiloxi C1-3, difluorometoxi, trifluorometoxi, metilsulfanilo, metilsulfinilo, metilsulfonilo, aminosulfonilo y fenilo, en el que el grupo fenilo puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de los otros entre fluor, metilo, metoxi, ciano e hidroxi; m representa 0 o 1; y en el que la parte alifática de la estructura de nucleo tricíclico de formula general (1) está sustituida con uno o dos grupos iguales o diferentes R8 se selecciona, independientemente entre sí, entre el grupo R8a que consiste en hidrogeno, metilo y etilo; los tautomeros de los mismos, los estereoisomeros de los mismos, las mezclas de los mismos y las sales de los mismos, aunque los siguientes compuestos de formulas (2) a (4) están excluidos.
ARP100104083A 2009-11-06 2010-11-04 Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen. AR078887A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09175233 2009-11-06

Publications (1)

Publication Number Publication Date
AR078887A1 true AR078887A1 (es) 2011-12-07

Family

ID=41683136

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104083A AR078887A1 (es) 2009-11-06 2010-11-04 Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.

Country Status (27)

Country Link
US (3) US8497281B2 (es)
EP (1) EP2496559B1 (es)
JP (1) JP5796015B2 (es)
KR (1) KR20120102688A (es)
CN (2) CN105037326A (es)
AP (1) AP2012006248A0 (es)
AR (1) AR078887A1 (es)
AU (1) AU2010315077B2 (es)
BR (1) BR112012010792A2 (es)
CA (1) CA2778161A1 (es)
CL (1) CL2012001043A1 (es)
CO (1) CO6531441A2 (es)
EA (1) EA022323B1 (es)
GE (1) GEP20156330B (es)
IL (1) IL218652A0 (es)
IN (1) IN2012DN02807A (es)
MA (1) MA33776B1 (es)
MX (1) MX2012005309A (es)
MY (1) MY159922A (es)
NZ (1) NZ598950A (es)
PE (1) PE20121182A1 (es)
PH (1) PH12012500904A1 (es)
SG (1) SG179569A1 (es)
TW (1) TWI531571B (es)
UA (1) UA109643C2 (es)
UY (1) UY33001A (es)
WO (1) WO2011057054A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329897B2 (en) 2007-07-26 2012-12-11 Vitae Pharmaceuticals, Inc. Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2704628C (en) * 2007-11-16 2016-11-29 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
US20110028445A1 (en) * 2008-02-12 2011-02-03 Boehringer Ingelheim International Gmbh Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8598160B2 (en) 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PL2300461T3 (pl) 2008-05-01 2013-09-30 Vitae Pharmaceuticals Inc Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1
US8569292B2 (en) 2008-05-01 2013-10-29 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CA2723034A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CL2009001151A1 (es) 2008-05-13 2010-08-13 Boehringer Ingelheim Int Compuestos derivados de acidos carbociclicos aliciclicos de benzomorfanos, procedimiento de preparacion, composicion farmaceutica, utiles para tratar enfermedades influenciadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa, como trastornos metabolicos.
JP5379160B2 (ja) 2008-07-25 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201022266A (en) 2008-10-23 2010-06-16 Boehringer Ingelheim Int Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
EP2438049B1 (en) 2009-06-02 2014-05-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
TWI531571B (zh) * 2009-11-06 2016-05-01 維它藥物公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
WO2012059416A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
TWI537258B (zh) * 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
EP2846797A1 (en) 2012-05-09 2015-03-18 Boehringer Ingelheim International GmbH Pharmaceutical combinations for the treatment of metabolic disorders
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US20150141651A1 (en) * 2013-11-20 2015-05-21 Boehringer Ingelheim International Gmbh Hexahydroindenopyridine derivatives
CN109045035B (zh) * 2018-07-19 2020-07-28 广西科技大学 7-(2,2-二甲基-3-丁烯酰胺基)-八氢苯喹啉乙酸酯在制备治疗肝病药物的应用
AR127706A1 (es) * 2021-11-19 2024-02-21 Hoffmann La Roche Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona
CN116554000B (zh) * 2023-04-28 2025-07-25 南京林业大学 一种金属铑不对称催化二烷基取代的内炔制备茚醇的方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127995C (es) 1963-12-20 Geigy Ag J R
US3341538A (en) 1965-06-18 1967-09-12 Geigy Chem Corp Certain 2, 6-methano-3-benzazocines
DE1785124A1 (de) 1968-08-13 1971-11-11 Prym Werke William Reissverschluss
DE2108954A1 (en) 1971-02-25 1972-09-07 Boehringer Sohn Ingelheim 2-(furylmethyl)-6,7-benzomorphans - useful as cns active agents
GB1304175A (es) 1969-03-31 1973-01-24
DE2105743C3 (de) 1971-02-08 1979-11-29 Boehringer Sohn Ingelheim 2-(Furylmethyl)- a -5,9-dialkyl -6,7benzomorphane, Verfahren zu ihrer Herstellung und deren Verwendung
US3681349A (en) 1970-03-05 1972-08-01 Morton Norwich Products Inc 1-(substituted benzyl) tetrahydro-2-(1h) pyrimidones
US3657257A (en) 1970-08-31 1972-04-18 Robins Co Inc A H 3-aryl-8-carbamoyl nortropanes
DE2229695A1 (de) 1972-06-19 1974-01-31 Boehringer Sohn Ingelheim 2-(heteroaryl-methyl)-5,9 beta-dialkyl6,7-benzomorphane, deren saeureadditionssalze sowie verfahren zu deren herstellung
DE2338369A1 (de) 1973-07-26 1975-02-13 Schering Ag Mikrobiologische hydroxylierung von 2,6-methano-3-benzazocinen
SU511005A3 (ru) 1973-10-27 1976-04-15 К.Х.Берингер Зон., (Фирма) Способ получени (метоксиметилфурилметил)6,7-бензоморфанов или морфинанов
US4009171A (en) 1974-02-21 1977-02-22 Sterling Drug Inc. N-acylated-11-oxygenated-2,6-methano-3-benzazocine intermediates
DE2411382C3 (de) 1974-03-09 1979-09-06 C.H. Boehringer Sohn, 6507 Ingelheim 2-Tetrahydrofurfuryl-6,7-benzomorphane, Verfahren zur Herstellung und deren Verwendung
US4087532A (en) 1974-03-09 1978-05-02 Boehringer Ingelheim Gmbh Analgesically useful 2-tetrahydrofurfuryl-5-lower alkyl-2-oxy-6,7-benzomorphans and salts thereof
DE2437610A1 (de) 1974-08-05 1976-02-26 Boehringer Sohn Ingelheim Neue 5,9-beta-disubstituierte 2-tetrahydrofurfuryl-6,7-benzomorphane, deren saeureadditionssalze, ihre verwendung als arzneimittel und verfahren zu deren herstellung
US4108857A (en) 1975-08-18 1978-08-22 Sterling Drug Inc. Imidazolylmethyl methanobenzazocines
DE2828039A1 (de) 1978-06-26 1980-01-10 Boehringer Sohn Ingelheim 2-(2-alkoxyethyl)-2'-hydroxy-6,7-benzomorphane deren saeureadditionssalze diese enthaltende arzneimittel und verfahren zu deren herstellung
GB9510459D0 (en) 1995-05-24 1995-07-19 Zeneca Ltd Bicyclic amines
GB9517622D0 (en) 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
JP3192662B2 (ja) 1996-07-31 2001-07-30 日研化学株式会社 ６―フェニルテトラヒドロ―１，３―オキサジン―２―オン誘導体及びそれを含む医薬組成物
GB9623944D0 (en) 1996-11-15 1997-01-08 Zeneca Ltd Bicyclic amine derivatives
DE69816758T2 (de) 1997-05-20 2004-06-03 Heraeus Quarzglas Gmbh & Co. Kg Synthetisches quarzglas zur verwendung in uv-strahlung und verfahren zu seiner herstellung
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
WO2001055063A1 (en) 2000-01-25 2001-08-02 Idemitsu Petrochemical Co., Ltd. Novel bisadamantane compounds, process for preparing the same, and novel biadamantane derivatives
DE10034623A1 (de) 2000-07-17 2002-01-31 Bayer Ag Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
MXPA04011327A (es) 2002-05-17 2005-08-15 Jenken Biosciences Inc Opioides y compuestos similares a opioides y usos de los mismos.
JP2006521359A (ja) 2003-03-26 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としての二環式ピペリジン誘導体
EP1618090A1 (en) * 2003-04-11 2006-01-25 Novo Nordisk A/S 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
EP1862181A3 (en) * 2003-04-11 2010-09-15 High Point Pharmaceuticals, LLC New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
US7687644B2 (en) 2004-05-07 2010-03-30 Janssen Pharmaceutica Nv Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
UA89043C2 (ru) * 2004-05-07 2009-12-25 Инсайт Корпорейшн Амидосоединения и их применение как фармацевтических средств
KR101197672B1 (ko) 2004-08-30 2012-11-07 얀센 파마슈티카 엔.브이. 11-베타 하이드록시스테로이드 데하이드로게나제저해제로서 트리사이클릭 락탐 유도체
JP2008515956A (ja) 2004-10-12 2008-05-15 ノボ ノルディスク アクティーゼルスカブ １１β−ヒドロキシステロイドデヒドロゲナーゼ１型活性スピロ化合物
JP2008515972A (ja) 2004-10-13 2008-05-15 ニューロジェン・コーポレーション メラニン濃縮ホルモン受容体のリガンドとしてのアリール置換８−アザビシクロ［３．２．１］オクタン化合物
US20090264650A1 (en) 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
JP4880671B2 (ja) * 2005-04-05 2012-02-22 エフ．ホフマン−ラ ロシュ アーゲー １Ｈ−ピラゾール４−カルボキシルアミドその製造方法および１１β−ヒドロキシステロイドデヒドロゲナーゼとしてのその使用
EA200801492A1 (ru) 2005-11-01 2008-10-30 Транстек Фарма Фармацевтическое применение замещенных амидов
AU2006310518A1 (en) 2005-11-01 2007-05-10 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted amides
JP2007140188A (ja) 2005-11-18 2007-06-07 Fujifilm Corp ポジ型感光性組成物及びそれを用いたパターン形成方法
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2007081570A2 (en) 2005-12-30 2007-07-19 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
BRPI0707408A2 (pt) 2006-01-31 2011-05-03 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
AU2007240458B2 (en) 2006-04-21 2012-03-15 Eli Lilly And Company Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
PT2029529E (pt) 2006-04-24 2010-09-02 Lilly Co Eli Pirrolidinonas substituídas como inibidores de 11 betahidroxiesteróide desidrogenase
DK2035379T3 (da) 2006-04-25 2010-09-06 Lilly Co Eli Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
TW200811170A (en) 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
WO2008046758A2 (en) 2006-10-19 2008-04-24 F. Hoffmann-La Roche Ag Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
TW200829171A (en) 2006-11-17 2008-07-16 Nihon Nohyaku Co Ltd Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
EP2125750B1 (en) 2007-02-26 2014-05-21 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1
RU64276U1 (ru) 2007-03-01 2007-06-27 Открытое акционерное общество "Татнефть" им. В.Д. Шашина Трубная обвязка устьевой арматуры нагнетательной скважины
KR20100015414A (ko) 2007-03-09 2010-02-12 하이 포인트 파마슈티칼스, 엘엘씨 히드록시스테로이드 탈수소효소 억제제로서 인돌- 및 벤즈이미다졸 아미드
US8329897B2 (en) 2007-07-26 2012-12-11 Vitae Pharmaceuticals, Inc. Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2704628C (en) * 2007-11-16 2016-11-29 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
WO2009102428A2 (en) 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
US20110028445A1 (en) * 2008-02-12 2011-02-03 Boehringer Ingelheim International Gmbh Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8598160B2 (en) 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP5538356B2 (ja) 2008-03-18 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
PL2300461T3 (pl) 2008-05-01 2013-09-30 Vitae Pharmaceuticals Inc Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1
CA2723034A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5379160B2 (ja) 2008-07-25 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
TWI531571B (zh) * 2009-11-06 2016-05-01 維它藥物公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物

Also Published As

Publication number Publication date
CO6531441A2 (es) 2012-09-28
PE20121182A1 (es) 2012-09-10
WO2011057054A1 (en) 2011-05-12
AU2010315077B2 (en) 2015-04-16
CA2778161A1 (en) 2011-05-12
HK1175470A1 (zh) 2013-07-05
CN105037326A (zh) 2015-11-11
SG179569A1 (en) 2012-05-30
BR112012010792A2 (pt) 2016-03-29
CN102666491A (zh) 2012-09-12
US9663470B2 (en) 2017-05-30
TWI531571B (zh) 2016-05-01
IL218652A0 (en) 2012-05-31
US8497281B2 (en) 2013-07-30
EP2496559B1 (en) 2018-01-10
US20110136800A1 (en) 2011-06-09
MA33776B1 (fr) 2012-11-01
AU2010315077A1 (en) 2012-04-12
MY159922A (en) 2017-02-15
UY33001A (es) 2011-05-31
US20140031544A1 (en) 2014-01-30
CN102666491B (zh) 2015-06-24
UA109643C2 (uk) 2015-09-25
CL2012001043A1 (es) 2012-08-31
AP2012006248A0 (en) 2012-06-30
EP2496559A1 (en) 2012-09-12
EA022323B1 (ru) 2015-12-30
JP2013510168A (ja) 2013-03-21
MX2012005309A (es) 2012-09-28
EA201270562A1 (ru) 2012-09-28
US20160272590A1 (en) 2016-09-22
JP5796015B2 (ja) 2015-10-21
NZ598950A (en) 2014-05-30
US9328072B2 (en) 2016-05-03
PH12012500904A1 (en) 2015-02-20
KR20120102688A (ko) 2012-09-18
GEP20156330B (en) 2015-07-27
TW201132636A (en) 2011-10-01
IN2012DN02807A (es) 2015-07-24

Similar Documents

Publication Publication Date Title
AR078887A1 (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.
AR071719A1 (es) Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
PE20141010A1 (es) Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
AR070526A1 (es) Derivados de urea de benzomorfanos y estructuras relacionadas, una composicion farmaceutica que incluye al compuesto y un procedimiento de preparacion del mismo
RU2020112759A (ru) Гетероциклические соединения в качестве ингибиторов PAD
RU2009149185A (ru) Новое производное 1,2,2,4-тетрагидрохиноксалина, содержащее в качестве заместителя фенильную группу, имеющую структуру эфира сульфокислоты или амида сульфокислоты, и обладающее связывающей активностью в отношении рецептора глюкокортикоидов
PE20191349A1 (es) Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
PE20030535A1 (es) Derivados de naftiridin como inhibidores de isoenzima fosfodiesterasa de nucleotido ciclica
AR083724A1 (es) AZAESPIROHEXANONAS INHIBIDORAS DE LA 11b-HSD1 (11-b-HIDROXIESTEROIDE DESHIDROGENASA) UTILES PARA TRATAR DIABETES Y OTROS TRASTORNOS METABOLICOS, Y COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN
AR069545A1 (es) Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y
AR049139A1 (es) Compuestos derivados de benzamidas n - heterociclil - sustituidas como activadores de la glucoquinasa (glk), metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento en el tratamiento de la diabetes tipo ii.
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20141557A1 (es) Derivado de pirazoloquinolina
NZ599815A (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
KR960703852A (ko) 이환상 테트라하이드로 피라졸로피리딘(bicyclic tetrahydro pyrazolopyridines)
AR078841A1 (es) Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
RU2009143105A (ru) Производные пирролопиридина и их применение в качестве ингибиторов васе
HRP20131122T1 (hr) Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR066013A1 (es) Derivados de oxazolidinona, composiciones farmaceuticas que los contienen y su uso en el tratamiento o prevencion de una infeccion bacteriana.
PH12012502549A1 (en) Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure